Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Box: Driving adoption

    Hopes in the machine Driving adoption Data sharing among academia, industry and other healthcare stakeholders — along with standards for collecting and managing the data — will be necessary to improve accuracy and…

    Published on 1/23/2017
  • Hopes in the machine

    How machine learning is being used in drug R&D

    Data could start to read out in the next year on candidates designed from machine learning technologies that are being tested throughout R&D.

    Published on 1/23/2017
  • Box: Bitten by sound bites

    Duck and cover Bitten by sound bites Investors' fears that continued sound bites from President-elect Donald Trump could prolong the biopharma sector's woes are bearing out. Biotech and pharma indices tumbled …

    Published on 1/16/2017
  • Table: Drug-pricing levers

    Duck and cover Drug-pricing levers President-elect Donald Trump has taken a page from the Democrats' playbook by championing government "bidding" or negotiation for prescription drugs. Regardless of whether this …

    Published on 1/16/2017
  • Duck and cover

    Why biopharma is taking the risky approach of waiting for Trump to focus elsewhere

    Why biopharma is taking the risky approach of waiting for Trump to focus elsewhere, while shoring up alliances within Congress.

    Published on 1/16/2017
  • Tiers of disappointment

    Bad year for biotech ends on sour note in 4Q16 with all market cap tiers in red

    Biotech's bad year ended on an even more sour note with all market cap bands down significantly in 4Q16.

    Published on 1/9/2017
  • Figure: Money Raised in 2017

    Billion dollar baby Money Raised in 2017 Last week, the biotech industry raised $1.2 billion, bringing to $1.2 billion the total raised year-to-date. In 2016, a total of $84.6 billion was raised, including $49.4 …

    Published on 1/9/2017
  • Figure: Biotech fund flows

    Good riddance Biotech fund flows About $5 billion flowed out of biotech funds in 2016 vs. net inflows of $6 billion in 2015. November saw the largest inflows of the year — at $1.2 billion — as the BioCentury 100 …

    Published on 1/9/2017
  • Figure: M&A activity

    Good riddance M&A activity While the number of M&A deals in 2016 nearly kept pace with the prior year, aggregate value was down. Last year 84 deals were valued at $86 billion. In 2015, 85 deals were valued at a …

    Published on 1/9/2017
  • Figure: Raised by market cap

    Good riddance Raised by market cap Last year, 437 public companies raised $51.5 billion, representing 59% of the record-setting $86.7 billion raised by 501 companies in 2015. All market cap segments saw a decline …

    Published on 1/9/2017
  • Table: Follow-on performance

    Good riddance Follow-on performance Biotech companies raised $10.4 billion in 159 follow-ons in 2016, about one-third of the $29.6 billion raised in 224 offerings in 2015. Market caps for the 2016 class are down a…

    Published on 1/9/2017
  • Table: IPO performance

    Good riddance IPO performance Fifteen companies raised $4 billion in IPOs in 4Q16, bringing the total for the year to $7.2 billion. That's behind the $8.2 billion raised in 2015 but still the fourth-highest total …

    Published on 1/9/2017
  • Table: IPO queue

    Good riddance IPO queue At least nine companies have announced plans to go public since the start of 4Q16, bringing the IPO queue to at least 21. Unless noted, companies are seeking to list on NASDAQ. Filings are …

    Published on 1/9/2017
  • Figure: London vs. Europe

    Tiers of disappointment London vs. Europe For 2016, the BioCentury Europe index gained 11%, while the BioCentury London fell 2%. Ten of 19 continental European companies in the market cap-weighted benchmark …

    Published on 1/9/2017
  • Figure: Price-to-earnings: BT vs. RX

    Tiers of disappointment Price-to-earnings: BT vs. RX Biotech's average P/E ended 4Q at 18.5, up 2% from 3Q16 but down 23% from a year ago. While six of 10 big biotechs saw their multiples decline from 3Q16 to 4Q16…

    Published on 1/9/2017
  • Figure: Results by market cap

    Tiers of disappointment Results by market cap All market cap segments declined in 4Q16 to finish 2016 in the red. The under $200 million group trailed all tiers in 4Q by posting double-digit losses. For the year, …

    Published on 1/9/2017
  • Table: 4Q approvals

    Tiers of disappointment 4Q approvals Selected 4Q approvals. Company Approval Bristol-Myers Squibb Co. (NYSE:BMY) / Merck & Co. Inc. (NYSE:MRK) FDA approves Zinplava bezlotoxumab to reduce the recurrence of …

    Published on 1/9/2017
  • Table: Index performance

    Tiers of disappointment Index performance Index 4Q16 2016 BioCentury Europe 11% 11% DJIA 8% 13% S&P 500 3% 10% NASDAQ Composite 1% 8% NYSE Arca Pharmaceutical -6% -11% BioCentury London -6% -2%…

    Published on 1/9/2017
  • Good riddance

    Why investors think 2017 will be an up year for biotech despite macro uncertainty

    Investors hope low valuations and impoverished pipelines could drive enough M&A to boost biotech performance in 2017.

    Published on 1/9/2017
  • Delivering takeouts

    25th annual Buyside View sees investors eyeing mid-cap M&A targets in 2017

    BioCentury's 25th annual Buyside View finds investors eyeing mid-caps with late-stage or marketed products that could become M&A targets.

    Published on 1/2/2017
  • Table: Approval watch

    Delivering takeouts Approval watch Selected products up for approval in 2017. (A) Uses Enhanze recombinant human hyaluronidase (rHuPH20) drug delivery technology from Halozyme Therapeutics Inc. (NASDAQ:HALO); …

    Published on 1/2/2017
  • Table: New products to watch

    Delivering takeouts New products to watch Selected drugs that received regulatory approval in 2016. Reformulations and fixed-dose combinations with no new components are excluded. Source: BCIQ: BioCentury Online …

    Published on 1/2/2017
  • Table: Postlaunch report

    Delivering takeouts Postlaunch report Among more than 30 products that were first approved in 2015 and reported product-level sales for the first nine months of 2016, only Ibrance palbociclib from Pfizer Inc. (…

    Published on 1/2/2017
  • Table: Top biotech products

    Delivering takeouts Top biotech products At least 30 drugs developed and marketed by biotechs are expected to have more than $1 billion in 2016 sales. Antivirals from Gilead Sciences Inc. (NASDAQ:GILD) account for…

    Published on 1/2/2017
  • Not dead yet

    How to interpret CTAD data for Lilly, Biogen anti-amyloid mAbs in AD

    As Phase III failures continue to pile up, success for any anti-amyloid mAb is unlikely unless companies move earlier in the disease.

    Published on 12/19/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993